Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation often initially respond to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment but may acquire drug resistance due to multiple factors. MicroRNAs are a class of small noncoding and endoge...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Respir Dis
Main Authors: Wang, Fengfeng, Meng, Fei, Wong, Sze Chuen Cesar, Cho, William C.S., Yang, Sijun, Chan, Lawrence W.C.
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7303773/
https://ncbi.nlm.nih.gov/pubmed/32552611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466620915156
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados